Novo Nordisk and Eli Lilly face a looming patent cliff as top-selling GLP-1 obesity drugs like Ozempic and Mounjaro near loss of exclusivity. The companies are accelerating pipeline diversification into next-gen weight-loss therapies, Alzheimer’s, and cardiovascular treatments to offset revenue erosion. Investors question whether new products can match the blockbuster status of GLP-1s, pressuring valuations.
Novo Nordisk's key growth driver, semaglutide (Ozempic/Wegovy), faces US patent expirations starting in 2026. The article highlights that Novo is accelerating pipeline diversification but faces investor skepticism about replacing GLP-1 revenues.
- ▼ GLP-1 patent expirations threaten 50%+ revenue base
- ▼ Investor doubt on next-gen pipeline replacing GLP-1 sales
- ▲ Novo's next-gen obesity drugs could outperform expectations
- ▲ Biosimilar entry may be slower than anticipated due to manufacturing complexity
▼ Show FAQ (2) ▲ Hide FAQ
How much of Novo Nordisk's revenue comes from GLP-1 drugs?
Semaglutide-based products account for roughly 60% of total revenue, making the patent cliff a major risk.
What is the timeline for Ozempic patent expirations?
Key US patents begin expiring in 2026, with additional patents extending into the early 2030s for specific formulations.